F-1/A: Optimi Health Launches US IPO, Targets Nasdaq Listing

Optimi Health Corp., a Canadian GMP-compliant psychedelic drug manufacturer, is launching an initial public offering in the United States and applying for a Nasdaq listing, despite a history of operating losses and significant regulatory hurdles.

Summary

• Optimi Health Corp. is a Canadian GMP-compliant pharmaceutical drug manufacturer specializing in MDMA and psilocybin derived from botanical sources.
• The company operates two 10,000-square-foot production facilities in Princeton, British Columbia, under a Drug Establishment Licence (DEL) and a Dealers Licence (DL) from Health Canada.
• Products are currently available in Australia for prescription use in treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and in Canada via the Special Access Program (SAP).
• MDMA products are in Phase 2 clinical trials in Israel, a planned target market, and psilocybin products are in Phase 2b clinical trials in Canada, both conducted by third parties.
• The company is restricted from selling products in the United States, where psilocybin and MDMA are Schedule I controlled substances, but aims for future market entry.
• An initial public offering of 2,142,857 common shares is planned in the United States, with an expected price range of US$6.00 to US$8.00 per share.
• A 1-for-30 reverse share split is anticipated immediately prior to the effectiveness of the registration statement to meet Nasdaq's minimum share price requirement.
• The company reported a net loss of C$1,553,975 (US$1,133,296) for the three months ended December 31, 2025, and C$3,712,031 (US$2,665,349) for the fiscal year ended September 30, 2025.
• Accumulated deficit since inception reached C$28,311,788 (US$20,001,233) as of December 31, 2025.
• Net proceeds from the offering are estimated at approximately US$12.3 million (or US$14.3 million if the over-allotment option is fully exercised), intended for scaling production, market expansion (Israel and US), and general working capital.
• The company has a limited operating history and its ability to continue as a going concern is dependent on achieving profitability and raising additional capital.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company has strong foundational licenses and early market access in a high-growth sector, its significant accumulated losses and ongoing need for financing present considerable risks. The IPO is crucial for funding, but the long and uncertain path to profitability, especially in the U.S. market, tempers enthusiasm.

Positives

• Holds Canadian Good Manufacturing Practices (GMP) compliant Drug Establishment Licence (DEL) and Dealers Licence (DL) for controlled substances, differentiating it from many psychedelic sector companies still in clinical or pre-commercial phases.
• Currently supplying regulated MDMA and psilocybin medicines under prescription in Australia for PTSD and TRD, and via Canada's Special Access Program.
• Vertically integrated operations with two 10,000-square-foot production facilities in British Columbia, allowing for rapid scaling and quality control.
• Active research and development commitment, including supplying clinical trials in Canada and Israel, and continuous product improvement.
• Early-mover advantage in the prescription market for psychedelic drugs in Australia, positioning for future market expansions.
• Received FDA Establishment Identifier (FEI) number and appointed a U.S. Agent, key regulatory steps for future engagement in FDA filings and commercial supply into the United States.
• Directors forgave C$1,331,052 in compensation during fiscal year 2025, improving the company's financial position.

Negatives

• The company has a history of recurring operating losses, with a net loss of C$1,553,975 for Q1 FY2026 and C$3,712,031 for FY2025.
• An accumulated deficit of C$28,311,788 as of December 31, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• Significant reliance on additional financing to fund ongoing operations and future growth, with no assurance of obtaining such financing on favorable terms.
• The U.S. market, a key target, is currently restricted as psilocybin and MDMA are Schedule I controlled substances, requiring DEA rescheduling and FDA approval for broad market access.
• The company does not currently own any patents or have pending patent applications related to its MDMA and botanical psilocybin products, relying on proprietary know-how and trade secrets.
• Increased competition in the nascent psychedelic industry from more established companies with greater resources.
• Purchasers in this offering will experience immediate and substantial dilution in the book value of their investment due to the offering price being substantially higher than the pro forma net tangible book value per common share.

Risks

• Controlled substance regulatory compliance risks, including potential material adverse repercussions from violations of laws and regulations.
• Inability to receive and maintain necessary licenses and permits, which are crucial for operations and expansion.
• Material adverse impact from changes in U.S. legislative and regulatory policies, including tariffs and the uncertain rescheduling of MDMA and psilocybin by the DEA.
• Product liability claims and/or regulatory actions due to products being ingested by humans, potentially leading to increased costs, reputational damage, or business failure.
• The industry and market for psychedelic products are relatively new, with no guarantee of sustainable revenue streams or market growth.
• Limited operating history and challenges in managing growth, including scaling infrastructure, expanding sales, and retaining qualified employees.
• Dependence on third-party manufacturers and suppliers for critical raw materials and testing services, creating risks of production delays or quality control issues.
• Reliance on third parties to conduct clinical trials, with potential for delays, unsatisfactory performance, or failure to meet regulatory standards.
• Uncertainty in obtaining necessary regulatory approvals for product candidates, which is a lengthy, expensive, and unpredictable process.
• Research and development of drugs targeting the central nervous system (CNS) is particularly difficult, with high failure rates and challenges in predicting drug effects.
• Potential for side effects, adverse events, or other safety risks associated with product candidates, which could delay or halt clinical development or limit commercial potential.
• Failure to achieve market acceptance by physicians, patients, and third-party payers, even if regulatory approval is obtained.
• Inability to protect the confidentiality of trade secrets, which could materially adversely affect the value of product candidates and harm the business.
• Difficulty in enforcing judgments or bringing actions outside the United States against the company and its directors due to its Canadian incorporation and non-U.S. residency of key personnel.
• Potential classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could result in adverse tax consequences for U.S. Holders.

Future Outlook

The company intends to expand into additional markets such as Israel and the United States, continue investing in R&D for drug formulations, strengthen regulatory compliance, and collect real-world evidence for Australian regulatory submissions. It also plans further collaborations with healthcare providers and government agencies to advocate for psychedelic-assisted therapies. Margin expansion is anticipated through economies of scale, higher batch yields, automation, fixed-cost dilution, and GMP/DEL licensing advantages. The company expects to need additional funds for U.S. market entry after the next 12 months, as it does not anticipate gaining U.S. market entry within that timeframe.

Management Comments

• "We are a Canadian Good Manufacturing Practices (GMP) compliant, pharmaceutical drug manufacturer licensed by Health Canada for the handling of controlled substances and GMP production."
• "We specialize in controlled substances with our products being 3,4-Methylenedioxymethamphetamine hydrochloride (MDMA) and psilocybin derived from botanical sources."
• "Unlike most companies in the psychedelic sector that remain in clinical or pre-commercial phases, we are currently supplying regulated medicines under prescription in certain markets – supported by a DEL that also permits the legal manufacture and international export of both products."
• "By prioritizing sustainable and responsible production practices, we are dedicated to becoming a global leader in the psychedelic pharmaceutical sector."
• "Our research initiatives focus on optimizing extraction efficiency, improving formulation stability and ensuring scalable manufacturing techniques that align with future market expansion plans."
• "Our near-term results will be influenced by regulatory developments in key jurisdictions, order volume from existing partners, cost optimization through automation and disciplined capital deployment."
• "As international access expands, we believe we are well positioned to scale responsibly and grow our share of the emerging global market for psychedelic-assisted therapies."
• "We are in the process of permanently winding down the business segment that was responsible for the sale of nutraceutical products. We consider the assets, liabilities and operations of this business segment to be immaterial to our overall consolidated operations. While this business did contribute a significant portion of our historical revenue, it generated a net loss overall. The winding down of this business will bolster our financial performance given its history of recurring losses."
• "We believe we are strategically positioned to supply pharmaceutical-grade MDMA and psilocybin capsules to regulated treatment providers in the United States immediately following rescheduling and FDA approval events."
• "This capacity represents a first-mover foothold in a market where the majority of companies remain in pre-revenue clinical phases and lack commercial production authorization."

Industry Context

StockSavvy.ai notes that Optimi Health Corp. operates in the nascent but rapidly evolving psychedelic pharmaceutical sector, distinguishing itself by being a GMP-certified manufacturer with current commercial supply in regulated markets (Australia, Canada SAP) unlike many peers still in preclinical or early clinical stages. The company's vertical integration and licensing are key competitive advantages in an industry with high regulatory barriers. The focus on MDMA and psilocybin aligns with leading research trends for PTSD and TRD, which have received Breakthrough Therapy Designations from the FDA for other developers. However, the industry faces significant challenges including regulatory uncertainty, public perception, and the need for substantial capital for drug development and market expansion, particularly in the U.S. where these substances remain Schedule I.

Comparison to Industry Standards

• Unlike most companies in the psychedelic sector that remain in clinical or pre-commercial phases, Optimi Health is currently supplying regulated medicines under prescription in Australia and via Canada's Special Access Program.
• The company's GMP-compliant manufacturing facilities and Health Canada DEL differentiate it from other psychedelic manufacturers, enabling competitively priced products for human therapeutic use.
• The company's current production capacity of up to 100,000 PTSD patients (36,000g – 54,000g of MDMA) and 200,000 TRD patients (10,000g – 15,000g of psilocybin) annually positions it for significant market share upon U.S. rescheduling, compared to many pre-revenue clinical-stage companies.
• The company's FDA drug establishment registration (FEI) and U.S. Agent appointment provide a regulatory architecture for future lawful foreign manufacturer participation in the U.S. supply chain, a step ahead of many international competitors.

Management Changes

Corporate Governance

Legal Proceedings

• No material legal or arbitration proceedings are currently pending or, to the company's knowledge, threatened, which may have significant effects on its financial position or profitability.
• The company received a non-final office action letter from the USPTO, objecting to the registration of the Optimi and Optimi Health marks due to likelihood of confusion with four prior U.S. registered trademarks.
• The company received a cease and desist letter from a U.S. public company, alleging trademark infringement for the Optimi and Optimi Health marks.
• The company does not intend to continue pursuing registration of the Optimi and Optimi Health marks in the U.S. due to anticipated costs and time.

Related Party Transactions

• Dane Stevens (CEO, CMO, Director) and John James Wilson (Chairman) participated in multiple private placements, subscribing for units and convertible debentures.
• Catcher Investments Ltd., a company controlled by John James Wilson, provided a C$1,000,000 secured loan at 7.5% interest, maturing August 4, 2026.
• Catcher Investments Ltd. and Cathay Visions Enterprises Ltd. (controlled by Dane Stevens) subscribed for 3,000 and 450 convertible debentures, respectively, totaling C$3,450,000.
• The company has a lease agreement for its Princeton Facilities with BC Green Pharmaceuticals Inc., where Bryan Safarik (COO, Director) serves as President and COO, and Jacob Safarik (Interim CFO, Director) serves as CFO. The lease was amended on July 1, 2025, extending the term to June 30, 2030.
• During the fiscal year ended September 30, 2025, directors forgave an aggregate of C$1,331,052 in compensation owed to them, including C$451,238 from John James Wilson, C$258,595 from Dane Stevens, C$302,938 from Jacob Safarik, and C$318,281 from Bryan Safarik.
• As of December 31, 2025, C$917,869 was owing to key management (unsecured, without interest, due on demand).

Stakeholder Impact

• **Shareholders:** Potential for dilution from the IPO and future capital raises. Existing shareholders will experience immediate and substantial dilution. The reverse share split is a technical move for listing, not a direct value increase. The company's going concern risk poses a significant threat to shareholder value.
• **Employees:** The company has six full-time, four part-time employees, and one independent contractor. The winding down of the nutraceuticals business may impact employees in that segment. Equity incentive plans are in place to attract and retain talent.
• **Customers:** Current customers in Australia and Canada (SAP) benefit from the company's GMP-certified MDMA and psilocybin products. Expansion into new markets aims to broaden access to psychedelic-assisted therapies.
• **Suppliers:** The company relies on third-party suppliers for critical raw materials and GMP-compliant testing services. Disruptions in the supply chain or changes in supplier reliability could impact product availability.
• **Creditors:** The company has significant liabilities, including loans payable and convertible debentures, some from related parties. The debt forgiveness by directors is positive for creditors, but the overall going concern risk remains a concern for all creditors.

Next Steps

• Effect a 1-for-30 reverse share split immediately prior to the effectiveness of the registration statement.
• Complete the initial public offering of common shares in the United States.
• List common shares on the Nasdaq Capital Market under the trading symbol OPTH.
• Scale production and distribution of products in current markets (Australia, Canada).
• Prepare for additional market entry to Israel and the United States.
• Continue to invest in research and development for drug formulations.
• Continue to strengthen regulatory compliance.
• Continue to collect real-world evidence (RWE) and patient-reported outcomes (PROs) for regulatory submissions in Australia.
• Further collaborations with healthcare providers and government agencies to advocate for safe and effective psychedelic-assisted therapies.
• Complete the Drug Master File (DMF) in Canada for psilocybin.
• Await confirmation from ATMA CENA Healthcare Solutions regarding next steps under their supply agreement for psilocybin extract for a phase II clinical trial.
• Develop and validate testing methodologies according to USP or EP standards, validate instrumentation and software, staff the analytical laboratory, and complete QMS requirements for GMP to generate complete Certificates of Analysis (COAs) in-house.
• Advance the scale-up of the encapsulation program by validating an automatic encapsulator.

Key Dates

Recommendation

Optimi Health Corp. presents a high-risk, high-reward investment profile. The company's GMP certifications, vertical integration, and early market access in Australia and Canada are strong competitive advantages in the emerging psychedelic pharmaceutical sector. However, the significant accumulated losses, ongoing need for substantial financing, and the inherent regulatory uncertainties, particularly regarding U.S. market entry, make it a speculative investment. The planned IPO is critical for funding, but the immediate dilution for new investors and the 'going concern' doubt are notable concerns. A 'hold' recommendation is appropriate for investors who are already exposed to the stock and are willing to tolerate high risk for potential long-term growth, while new investors should approach with extreme caution due to the financial instability and regulatory hurdles.

Keywords

Psychedelic pharmaceuticals, MDMA, Psilocybin, Health Canada, GMP manufacturing, SEC filing, Nasdaq IPO, Controlled substances, Treatment-resistant depression, Post-traumatic stress disorder, Clinical trials, Regulatory approval, Biotechnology, Pharmaceuticals, Drug development, Medical cannabis, Mental health therapies